Phaseline

Targets › RTASE

RTASE: drug programs, companies and trials

1 program from 1 company in 14 trials: 5 Phase 3, 4 Phase 2, 3 Phase 4, 2 Phase 1; Infectious disease, Metabolic and endocrine, Oncology; next expected readout Mar 2027.

Open in Phaseline: the race on RTASE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKDolutegravir
Human immunodeficiency virus type 1 integrase inhibitor
INSTI, RTASE, INTEGRASE, RTPhase 3HIV; HIV Infections; HIV-1-infection; Acute HIV Infection …Mar 2027

Conditions

HIV-1-infection (5) HIV Infections (3) HIV (2) Acute HIV Infection (1) Healthy Volunteer (1) HTLV-1 Infection (1) Tuberculosis (1)

Modalities

mixed (1)

Companies

GSK (1)

Related targets

INSTI (1) INTEGRASE (1) RT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.